肾上腺素剂量对院外心脏骤停神经功能结局的影响:一项全国性倾向评分分析
基于法国国家心脏骤停注册研究,纳入2011年7月1日至2019年1月1日期间27 309例院外心脏骤停患者,按接受的肾上腺素累积剂量分为推荐剂量组、高剂量组和低剂量组,采用多重倾向评分调整比较结局。主要终点为30天良好神经功能结局(脑功能分类CPC<3)。调整后高剂量组良好神经功能结局率显著更低(OR 0.6,95%CI 0.5-0.7),低剂量组与推荐剂量组无显著差异(OR 0.8,95%CI 0.7-1.1);高剂量组出院生存率也低于标准组(OR 0.5,95%CI 0.5-0.6)。全院外心脏骤停队列中仅588例(2.2%)存活且CPC良好。
要点
- 法国全国注册研究27 309例院外心脏骤停患者中,仅588例(2.2%)存活且30天CPC<3。
- 倾向评分调整后,高剂量肾上腺素组30天良好神经功能结局率显著低于推荐剂量组(OR 0.6,95%CI 0.5-0.7)。
- 低剂量肾上腺素组30天良好神经功能结局与推荐剂量组无显著差异(OR 0.8,95%CI 0.7-1.1)。
- 高剂量组出院生存率低于标准组(OR 0.5,95%CI 0.5-0.6)。
- 队列平均年龄68(57-78)岁,11.2%为心室颤动。
适用人群与场景
- 法国国家心脏骤停注册研究中纳入的院外心脏骤停患者,纳入时间2011年7月1日至2019年1月1日。
- 平均年龄68(57-78)岁,11.2%为心室颤动。
诊断标准与关键阈值
- 良好神经功能结局定义为30天脑功能分类(CPC)评分<3。
研究设计与关键结果
- 研究设计:基于法国国家心脏骤停注册研究的全国性倾向评分分析,纳入27 309例院外心脏骤停患者,按肾上腺素累积剂量分为推荐剂量组、高剂量组和低剂量组。
- 主要终点:30天良好神经功能结局(CPC<3),全队列588例(2.2%)存活且CPC良好。
- 调整后高剂量组30天良好神经功能结局率显著低于推荐剂量组(OR 0.6,95%CI 0.5-0.7)。
- 调整后低剂量组30天良好神经功能结局与推荐剂量组无显著差异(OR 0.8,95%CI 0.7-1.1)。
- 高剂量组出院生存率低于标准组(OR 0.5,95%CI 0.5-0.6)。
- 次要终点包括自主循环恢复和出院生存率。
证据类型、等级与局限
- 证据类型:基于全国注册数据的倾向评分分析(观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为,使用较低剂量肾上腺素与30天良好神经功能生存无显著差异;而较高剂量肾上腺素与良好神经功能生存率和30天生存率更低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Adrenaline is recommended during cardio-pulmonary resuscitation. The optimal dose remains debated, and the effect of lower than recommended dose is unknown.
OBJECTIVE: To compare the outcome of patients treated with the recommended, lower or higher cumulative doses of adrenaline.
DESIGN, SETTINGS, PARTICIPANTS: Patients were included from the French National Cardiac Arrest Registry and were grouped based on the received dose of adrenaline: recommended, higher and lower dose.
OUTCOME MEASURES AND ANALYSIS: The primary endpoint was good neurologic outcome at 30 days post-OHCA, defined by a cerebral performance category (CPC) of less than 3. Secondary endpoints included return of spontaneous circulation and survival to hospital discharge. A multiple propensity score adjustment approach was performed.
MAIN RESULTS: 27 309 patients included from July 1st 2011 to January 1st 2019 were analysed, mean age was 68 (57-78) years and 11.2% had ventricular fibrillation. 588 (2.2%) patients survived with a good CPC score. After adjustment, patients in the high dose group had a significant lower rate of good neurologic outcome (OR, 0.6; 95% CI, 0.5-0.7). There was no significant difference for the primary endpoint in the lower dose group (OR, 0.8; 95% CI, 0.7-1.1). There was a lower rate of survival to hospital discharge in the high-dose group vs. standard group (OR, 0.5; 95% CI, 0.5-0.6).
CONCLUSION: The use of lower doses of adrenaline was not associated with a significant difference on survival good neurologic outcomes at D30. But a higher dose of adrenaline was associated with a lower rate of survival with good neurological outcomes and poorer survival at D30.
参考来源
- Jaeger D, Baert V, Javaudin F, et al. Effect of adrenaline dose on neurological outcome in out-of-hospital cardiac arrest: a nationwide propensity score analysis. Eur J Emerg Med. 2022. PMID: 34908000. doi:10.1097/MEJ.0000000000000891
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。